leisure time -WSS

leisure time

author：leisure time 2025-09-03 07:53:58 - browse：6

Electrocardiogram in the shape of the United States map — Adobe

The market for artificial intelligence in health care is about as transparent as a brick wall. New tools achieve impressive results in published studies. But it is often difficult to compare them head to head with similar products, or tell whether they will work on different kinds of patients.

A new company is promising to change that — if it can convince AI developers to expose their products to more rigorous testing.

Called Dandelion Health, the New York-based firm is launching a first-of-its-kind public service to evaluate AI products on independent data designed to root out weaknesses and reveal bias. The company said Wednesday its initial pilot program, to begin next month, will focus on testing algorithms that use electrocardiograms to predict heart conditions.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

focus

WSS

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

How to address the problem of discarded donor organs

Readout LOUD podcast: Merger Mondays, Ozempic panic

What the Wegovy shortage looks like for doctors — and for patients

Obesity now affects over 1 billion people worldwide, study finds

focus

leisure time

hotspot

Psychedelics group wrestles with new pharma identity

AstraZeneca loses challenge to Medicare drug price negotiation

ChatGPT in medicine: STAT answers readers' burning questions

International team creates first chimeric human

23andMe had bad news about my health. I wish a person had delivered it

Nick Jonas talks about managing diabetes along with his career

FDA approval of Sarepta Duchenne genetic therapy gives me hope

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

How to save PrEP access — and even expand it

STAT Readout: Today's biotech news includes Sana and Amylyx

Wikipedia

Female surgeons have lower rates of long

Change Healthcare cyberattack outage could last weeks

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

An inside look at PIPEs, biotech's buzzy new financing tool

European regulators recommend Amylyx's ALS drug be rejected

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

knowledge

focus

focus

leisure time